A

Subgroup	Olanzapine		Placebo		Risk Difference	
	No appetite loss	Total	No appetite loss	Total	%	95%CI
Overall	89	208	40	180	20.6	(11.5 to 29.6)
Age						
<72 years	37	97	16	57	17.4	(4.1 to 30.6)
≥72 years	52	111	24	123	23.5	(11.2 to 35.9)
Sex						
Male	76	168	34	140	21.0	(10.6 to 31.3)
Female	13	40	6	40	17.5	(-0.8 to 35.8)
Performance status						
0	68	161	32	133	18.2	(7.6 to 28.7)
1-2	21	47	8	47	27.7	(9.8 to 45.5)
Drinking habits						
Yes	38	88	17	59	14.4	(-1.1 to 29.9)
No	51	120	23	121	23.5	(12.2 to 34.8)
Chemotherapy						
Pemetrexed	23	61	10	63	21.8	(6.7 to 37.0)
Paclitaxel	15	35	3	26	31.3	(10.8 to 51.8)
Nab-paclitaxel	25	60	15	52	12.8	(-4.7 to 30.3)
Etoposide	26	49	12	38	21.5	(1.1 to 41.8)
5-HT receptor antagonist						
Granisetron	18	50	6	41	21.4	(4.2 to 29.9)
Palonosetron	70	158	34	139	20.1	(9.6 to 30.7)



B

Subgroup	Olanzapine		Placebo		Risk Difference	
	CR	Total	CR	Total	%	95%CI
Overall	183	208	145	180	7.4	(0.1 to 14.7)
Age						
<72 years	85	97	63	57	5.8	(-5.0 to 16.6)
≥72 years	98	111	82	123	8.7	(-1.1 to 18.5)
Sex						
Male	147	168	113	140	6.8	(-1.4 to 15.0)
Female	36	40	32	40	10.0	(-5.5 to 25.5)
Performance status						
0	143	161	110	133	6.1	(-1.9 to 14.2)
1-2	40	47	35	47	10.6	(-5.5 to 26.7)
Drinking habits						
Yes	82	88	51	59	6.7	(-3.5 to 16.9)
No	101	120	94	121	6.5	(-3.4 to 16.4)
Chemotherapy						
Pemetrexed	52	61	45	63	13.8	(-0.5 to 28.1)
Paclitaxel	32	35	24	26	-0.9	(-14.7 to 12.9)
Nab-paclitaxel	53	60	44	52	3.7	(-9.0 to 16.5)
Etoposide	43	49	31	38	6.2	(-9.2 to 21.5)
5-HT receptor antagonist						
Granisetron	42	50	28	41	15.7	(-1.8 to 33.2)
Palonosetron	140	157	117	139	5.0	(-2.8 to 12.8)